Feature | November 12, 2012

GE Healthcare Acquires U-Systems, Expands Presence in Breast Cancer Detection

ABUS is first FDA-cleared automated breast ultrasound screening system for women with dense breasts

SOMO-V, SOMOV, ABUS, GE U-SYSTEMS

November 12, 2012 — GE Healthcare announced it has acquired U-Systems Inc., which recently gained U.S. Food and Drug Administration (FDA) clearance for the somo•v Automated Breast Ultrasound System (ABUS). It is the first ultrasound system on the market for breast cancer screening as an adjunct to mammography for asymptomatic women with greater than 50 percent dense breast tissue and no prior breast interventions. Financial terms were not disclosed.

The issue of breast density has become a national healthcare concern, as dense breast tissue makes it very difficult to detect early cancers. In addition to missed cancers, dense tissue is often misinterpreted as cancer, resulting in large numbers of needless breast biopsies. In addition, several states have enacted or are discussing legisation requiring doctors to notify patients if they have dense breasts. New screening systems, such as ABUS, are being introduced as an adjunct to mammagraphy for women with dense breast tissue. 
 
“The combination of U-Systems Inc. and GE Healthcare uniquely positions GE to offer U.S. healthcare providers and their patients the most comprehensive portfolio of breast care innovations on the market — from screening to diagnosis to monitoring,” said Tom Gentile, president and CEO of GE Healthcare Systems. “In addition to digital mammography and breast MR [magnetic resonance], GE can now offer breast screening ultrasound technology to our customers to help in early detection, which provides for more treatment options.”
 
According to a published study in the New England Journal of Medicine, women with dense tissue in 75 percent or more of the breast have a risk of breast cancer four to six times greater than the risk among women with little or no dense tissue (Boyd, et al. New England Journal of Medicine 2007;356:227-36M). Since dense breast tissue decreases mammography’s effectiveness in detection, the somo•v ABUS has proven to be an advancement in the visualization of cancer-hiding tissue in dense breasts.
 
??“What 3-D ultrasound will allow us to do is help us use the information that we get from mammography and integrate that information together with the information we get from ultrasound to find more cancers,” said Rachel Brem, M.D., principal investigator of the SOMO-INSIGHT clinical study examining whether full-field digital mammography (FFDM) along with the somo•v could improve breast cancer detection when compared to mammography alone in women with dense breasts. “Mammography is an effective tool at finding breast cancer, but it doesn’t work equally well in everyone. Recently completed studies demonstrated with the addition of somo•v ABUS, we find about 30 percent more cancers in women who have a normal mammogram, normal physical examination and dense breasts. For the more than 40 percent of women who have dense breasts, this is a significant advancement in their breast healthcare."
 
"We are very excited to become part of GE Healthcare's team," said Ron Ho, U-Systems president and CEO. "The worldwide resources of GE Healthcare will allow us to expand and accelerate our efforts to commercialize the recently FDA-approved somo•v ABUS. With our combined resources and capabilities, we have the opportunity to make a significant impact on breast cancer detection and patient outcomes around the world. We are thrilled to have the opportunity to continue to develop new technologies, products and applications for breast cancer screening."
 
The somo•v ABUS received FDA approval in September 2012 for breast cancer screening in the United States, and has also been indicated for screening in Canada and the European Union.?? U-Systems has operations in Sunnyvale, Calif., and Phoenix.  
 

Related Content

Joseph J. Cappello Named Executive Director of Are You Dense Nonprofits
News | Breast Density | February 20, 2019
The boards of Are You Dense Inc. and Are You Dense Advocacy Inc., founded by the late Nancy M. Cappello, Ph.D.,...
Congress Directs FDA to Establish Federal Breast Density Inform Standard
News | Breast Density | February 19, 2019 | Jeff Zagoudis, Associate Editor
As part of a federal spending bill passed late Friday, Congress directed the U.S. Food and Drug Administration (FDA) to...
Densitas Enters Partnership Agreement With TeleMammography Specialists
News | Breast Density | February 14, 2019
Breast imaging analytics company Densitas Inc. announced a new collaboration partnership with TeleMammography...
Hologic Launches Unifi Analytics Business Intelligence Tool
Technology | Analytics Software | February 12, 2019
Hologic Inc. announced the U.S. launch of Unifi Analytics, a business intelligence tool that allows healthcare...
Mount Sinai's Digital 3-D Mammography Van Rolls Into New York City
News | Mammography | February 11, 2019
Mount Sinai Hospital recently launched the Mount Sinai Mobile Mammography Program (MMP), bringing essential breast...
breast density cancer awareness
News | Breast Density | February 08, 2019
Governor Michelle Lujan Grisham has signed breast density inform bill, ...
Siemens Healthineers Syngo.Breast Care Adding AI-Based Decision Support
News | Clinical Decision Support | February 05, 2019
Siemens Healthineers showcased the new planned artificial intelligence (AI)-based features with its mammography reading...
 Volpara Solutions Launches Next-Generation VolparaDensity Software to Support SmartCurve Paddles
Technology | Breast Density | January 31, 2019
Volpara Solutions Inc. received U.S. Food and Drug Administration (FDA) 510(k) clearance for new technologies used in...
QTbreasthealth Opens New Breast Ultrasound Imaging Center in Grand Rapids
News | Ultrasound Women's Health | January 30, 2019
January 30, 2019 — QTbreasthealth launched a center in Grand Rapids, Mich., featuring its quantitative transmission
Traditional mammography continues to be the gold standard for breast cancer screening technologies. However, use of 3-D breast tomosynthesis is growing rapidly.

Traditional mammography continues to be the gold standard for breast cancer screening technologies. However, use of 3-D breast tomosynthesis is growing rapidly.

Feature | Breast Imaging | January 30, 2019 | By Jeff Zagoudis
The importance of early detection of...